文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

参附注射液联合复苏后集束化治疗对院内心脏骤停自主循环恢复患者疗效与安全性的随机对照研究

Efficacy and Safety of Combination Therapy of Shenfu Injection and Postresuscitation Bundle in Patients With Return of Spontaneous Circulation After In-Hospital Cardiac Arrest: A Randomized, Assessor-Blinded, Controlled Trial.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论院内心脏骤停自主循环恢复后,在集束化治疗基础上加用参附注射液100 mL持续静脉输注、每日两次,可提高28天和90天生存率。

该研究为前瞻性随机对照试验,纳入中国50家医院2012至2015年成人院内心脏骤停自主循环恢复患者,共978例分入对照组(486例)和参附注射液组(492例)。参附组在标准化复苏后集束化治疗基础上加用参附注射液100 mL持续静脉输注、每日两次,用至14天或出院。参附组28天生存率42.7%高于对照组30.1%,90天生存率39.6%高于对照组25.9%,28天死亡风险HR 0.61(95%CI 0.43-0.89,P=0.009)、90天死亡风险HR 0.55(95%CI 0.38-0.79,P=0.002)。参附组机械通气时间8.6±3.2天短于对照组12.7±7.9天,住院时间8.7±5.9天短于对照组13.2±8.1天(均P<0.001),未记录严重药物相关不良事件。

要点

  • 院内心脏骤停自主循环恢复后,在集束化治疗基础上加用参附注射液100 mL持续静脉输注、每日两次,28天生存率42.7% vs 对照组30.1%。
  • 参附组90天生存率39.6%高于对照组25.9%,90天死亡风险HR 0.55(95%CI 0.38-0.79,P=0.002)。
  • 参附组28天死亡风险HR 0.61(95%CI 0.43-0.89,P=0.009),低于对照组。
  • 参附组机械通气时间8.6±3.2天短于对照组12.7±7.9天,住院时间8.7±5.9天短于对照组13.2±8.1天(均P<0.001)。
  • 两组主要死亡原因均为不可逆脑损伤,未记录严重药物相关不良事件。

适用人群与场景

  • 中国50家医院2012至2015年成人院内心脏骤停并恢复自主循环的患者。

处置流程与药物剂量

  • 所有患者接受标准化复苏后集束化治疗。
  • 参附注射液组在集束化治疗基础上加用参附注射液100 mL持续静脉输注、每日两次,疗程14天或至出院。

研究设计与关键结果

  • 研究类型为前瞻性随机对照临床试验,纳入978例患者,参附注射液组492例、对照组486例。
  • 主要终点28天生存率:参附组42.7% vs 对照组30.1%。
  • 90天生存率:参附组39.6% vs 对照组25.9%。
  • 28天死亡风险:HR 0.61(95%CI 0.43-0.89,P=0.009);90天死亡风险:HR 0.55(95%CI 0.38-0.79,P=0.002)。
  • 机械通气时间:参附组8.6±3.2天 vs 对照组12.7±7.9天(P<0.001);住院时间:参附组8.7±5.9天 vs 对照组13.2±8.1天(P<0.001)。
  • 两组主要死亡原因均为不可逆脑损伤,未记录严重药物相关不良事件。

证据类型、等级与局限

  • 证据类型:前瞻性、随机、评估者盲法、对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于院内心脏骤停自主循环恢复的患者,在常规复苏后集束化治疗基础上联合参附注射液可改善临床结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Postresuscitation care bundle treatment after return of spontaneous circulation in patients experiencing in-hospital cardiac arrest can improve patients' survival and quality of life. The aim of the study was to evaluate the efficacy and safety of combined therapy of Shenfu injection and postresuscitation care bundle in these patients.

DESIGN: Prospective, randomized, controlled clinical study.

SETTING: Fifty hospitals in China.

PATIENTS: Adult patients had experienced in-hospital cardiac arrest between 2012 and 2015.

INTERVENTIONS: Based on the standardized postresuscitation care bundle treatment, patients were randomized to a Shenfu injection group (Shenfu injection + postresuscitation care bundle) or control group (postresuscitation care bundle) for 14 days or until hospital discharge. In the Shenfu injection group, 100 mL Shenfu injection was additionally administered via continuous IV infusion, bid.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day survival after randomization. The secondary outcomes included 90-day survival as well as the duration of mechanical ventilation and the hospital stay and the total cost of hospitalization. Of 1,022 patients enrolled, a total of 978 patients were allocated to the two groups: the control (n = 486) and Shenfu injection (n = 492) groups. The Shenfu injection group had a significantly greater 28-day survival rate (42.7%) than the control group (30.1%). Also, the Shenfu injection group had a significantly higher survival rate at 90 days (39.6%) than the control group (25.9%). Compared with patients in the control group, patients in the Shenfu injection group had lower risks of 28-day mortality (hazard ratio, 0.61; 95% CI, 0.43-0.89; p = 0.009) and 90-day mortality (hazard ratio, 0.55; 95% CI, 0.38-0.79; p = 0.002). In the Shenfu injection group, the duration of mechanical ventilation (8.6 ± 3.2 vs 12.7 ± 7.9 d; p < 0.001) and the hospital stay (8.7 ± 5.9 vs 13.2 ± 8.1 d; p < 0.001) were significantly less than in the control group. Irreversible brain damage was the main cause of death in both groups. No serious drug-related adverse event was recorded.

CONCLUSIONS: This study demonstrates that Shenfu injection in combination with conventional postresuscitation care bundle treatment is effective at improving clinical outcomes in patients with return of spontaneous circulation after in-hospital cardiac arrest.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Zhang Q, Li C, Shao F, et al. Efficacy and Safety of Combination Therapy of Shenfu Injection and Postresuscitation Bundle in Patients With Return of Spontaneous Circulation After In-Hospital Cardiac Arrest: A Randomized, Assessor-Blinded, Controlled Trial. Crit Care Med. 2017. PMID: 28661970. doi:10.1097/CCM.0000000000002570

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。